Fate Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Fate Therapeutics, Maintains $5 Price Target
H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Hold Rating, Maintains Target Price $5
Fate Therapeutics: Hold Rating Amid Financial Stability and Upcoming Milestones
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Fate Therapeutics (FATE)
Leerink Partners Maintains Fate Therapeutics(FATE.US) With Buy Rating
Fate Therapeutics' Promising Outlook: Buy Rating on Innovative Cell Therapy Programs FT819 and FT522
Fate Therapeutics (FATE) Gets a Hold From Stifel Nicolaus
Fate Therapeutics: Hold Rating Amidst Steady Q2 Financials and Clinical Progress
A Quick Look at Today's Ratings for Fate Therapeutics(FATE.US), With a Forecast Between $5 to $10
A Quick Look at Today's Ratings for Fate Therapeutics(FATE.US), With a Forecast Between $5 to $10
Wedbush Reaffirms Their Hold Rating on Fate Therapeutics (FATE)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Achieve Life Sciences (ACHV) and Kezar Life Sciences (KZR)
Fate Therapeutics Analyst Ratings
Fate Therapeutics (FATE) Receives a Buy From Barclays
TD Cowen Reaffirms Their Hold Rating on Fate Therapeutics (FATE)
Fate Therapeutics Analyst Ratings
HC Wainwright & Co. : Maintain the Fate Therapeutics (FATE.US) rating, adjust from neutral to neutral, and adjust the target price from $7.00 to $5.00.
Fate Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Neutral on Fate Therapeutics, Lowers Price Target to $5